Adaptation: For locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one previous chemotherapy regimen
Pharmacology: Erlotinib is an inhibitor of epidermal growth factor receptor tyrosine kinase. Erlotinib can compete with ATP to bind the intracellular catalytic region of epidermal growth factor receptor tyrosine kinase, inhibit phosphorylation, block and inhibit the system's transmission of intranuclear information, and thus prevent tumor growth, control cell proliferation, neovascularization and tumor metastasis